Company: CMND
Filing Date: 2025-03-18
Form Type: 6-K
Source: 0001013762-25-000571
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-18
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: March 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

Attached hereto and incorporated
herein is the Registrant’s press release issued on March 18, 2025, titled “Clearmind Medicine Announces Initiation of First
in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients”.

The first paragraph of the
press release attached to this Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements
on Form F-3 (File Nos.333-275991, 333-270859, 333-273293) and Form S-8
(File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit No. |     |                                                                                                                                                 |
| 99.1        |     | Press release titled: “Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients” |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: March 18, 2025 | Clearmind Medicine, Inc. 
 (Registrant)             
 By:                      | /s/ Adi Zuloff-Shani    |
|:---------------------|:----------------